Recent Updates
Recently added Catalysts

C105

Phase 2

Cognition Disorders | Small molecule | Immunology |Cognition Therapeutics, Inc.|Last Updated: May 28, 2008

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindUNCONTROLLEDBiomarker
Total Trials1
Total Enrollment150
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00529581A Study of C105 on Cognitive Dysfunction in Persons With Multiple SclerosisPHASE2 COMPLETED 150Nov 1, 2006Apr 1, 2008May 28, 200830 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Symbol Digit Modalities Test, Oral Version (SDMT) - Total # Correct
Change from baseline
Subject's Global Assessment of Cognitive Change
Change from baseline
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT
Interventions
NameTypeDescription
C105DRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 65 Years
SexALL
Healthy VolunteersNo
Study Sites30

Inclusion Criteria: * Males/females at least 18 years old and \< 65 years old, capable of understanding and complying with the protocol, including speaking and writing fluent English and having at least a 9th grade education * Clinically definite diagnosis per McDonald criteria of Multiple Sclerosi...

Countries:United States
Unlock Eligibility Criteria